Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Melanoma 236Carcinoma, Non-Small-Cell Lung 78Carcinoma, Renal Cell 61Neoplasm Metastasis 52Neoplasms 47Prostatic Neoplasms 34Uveal Melanoma 29Lung Neoplasms 28Pancreatic Neoplasms 27Carcinoma, Hepatocellular 25Brain Neoplasms 23Sarcoma 22Colorectal Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Skin Neoplasms 17Kidney Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Mesothelioma 13Uterine Cervical Neoplasms 12Recurrence 12Glioblastoma 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

Mifepristone 3Corlux 3Thyrotropin-Releasing Hormone 1Sodium Chloride 1Saline Solution 1Nivolumab 1LY2940680 1Ipilimumab 1Hydrocortisone 1Human Growth Hormone 1Diazoxide 1Dexmedetomidine 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Diseases × Ipilimumab × Clear all
NCT04042753 2026-06-02

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
10 enrolled
Endocrine

Pituitary Diseases, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡